A Randomized Trial Comparing Combined Basal Insulin/Glargine and Exenatide Therapy (BET) with Combined Basal Insulin/Glargine and Bolus Insulin/Humalog Lispro Therapy (BBT) in Subjects with Type 2 Diabetes, Being Treated by Glargine with Metformin Alone or with Combination of Metformin with Sulfonylurea.

Trial Profile

A Randomized Trial Comparing Combined Basal Insulin/Glargine and Exenatide Therapy (BET) with Combined Basal Insulin/Glargine and Bolus Insulin/Humalog Lispro Therapy (BBT) in Subjects with Type 2 Diabetes, Being Treated by Glargine with Metformin Alone or with Combination of Metformin with Sulfonylurea.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Exenatide; Insulin glargine; Insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by UKCRN.
    • 26 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top